Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor ⍺ antagonist etanercept - 01/09/11
Abstract |
The treatment of cicatricial pemphigoid is generally regarded as difficult and usually relies on individual clinical experience. Corticosteroids, as drugs of first choice, often have to be combined with steroid-sparing agents to prevent hazardous, long-term side effects. We describe a 72-year-old woman with long-standing cicatricial pemphigoid recalcitrant to established treatment regimens who responded rapidly and lastingly to therapy with the tumor necrosis factor ⍺ antagonist etanercept. To our knowledge, this is the first report of its use in the treatment of a bullous autoimmune disease. (J Am Acad Dermatol 2002;46:113-5.)
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: None. |
|
Conflict of interest: None. |
|
Reprint requests: Dr med Nicolas Hunzelmann, Klinik und Poliklinik für Dermatologie und Venerologie, der Universität Köln, Joseph-Stelzmann-Str 9, 50924 Cologne, Germany. E-mail: nico.hunzelmann@uni-koeln.de. |
|
Published online Oct 25, 2001. |
Vol 46 - N° 1
P. 113-115 - janvier 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?